2. Professor of carbohydrate and L-dopa and their usage, toolkit

摘要

(a) Carbohydrates (b) drug mixtures and ingredients including carbohydrates and / or carbamazepines, and (c) methods and related conditions for the treatment of Parkinson's disease, including carbohydrate and carbamazepine management in patients with the disease Parkinson's. 1. Characteristic requirement 1: a pharmaceutical mixture, including a first compound or medicament acceptable salt of the compound in structure consistent with the formula, wherein R1 and R2 are independently selected from the hydrogen group, - P (o) (OH) 832222;y -R -O-P (O) (OH)e. R83099a is c83321c83183248a - tar; r8310a is hydrogen, or c833183244a - tar; but there is at least one R1 and R2 es-p (o) (OH) 8322o-r83090-o-p (o) (OH) 832222;And the second compound, structurally equivalent to (2) or a pharmaceutically acceptable salt, in which R3 and r83088 are selected separately from the hydrogen group.y -R -O-P (O) (OH)R es un C -alquilo R es hidr geno o un C -alquilo y con la salvedad de que al menos uno de R y R es -P (O) (OH) o -R -OP (O) (OH) - Reivindicaci 25,898 ± 0.20, 26,338 ± 0.20, and 27,117 ± 0.20; or crystalline L-dopa 4-monophosphate anhydrate (ii) showing at least one characteristic peak in the powder X-ray diffraction pattern at 2q values of 8.468 ± 0.20, 10.234 ± 0.20, 11.821 ± 0 , 20, 13,084 ± 0.20, 13,503 ± 0.20, 15.48 ± 0.20, 15,848 ± 0.20, 16,513 ± 0.20, 18,447 ± 0.20, 19,346 ± 0.20, 20,239 ± 0 , 20, 21,139 ± 0.20, 24,221 ± 0.20, 24,865 ± 0.20, 25,647 ± 0.20. Claim 70: A crystalline carbidopa 3,4-diphosphate sodium salt showing at least one characteristic peak in the powder X-ray diffraction pattern at 2q values of 5,852 ± 0.20, 6,861 ± 0.20, 7,338 ± 0.20,11,159 ± 0.20, 11,729 ± 0.20, 12,953 ± 0.20, 13,714 ± 0.20, 14,381 ± 0.20, 14,686 ± 0.20, 15,479 ± 0.20, 16,676 ± 0.20, 17,179 ± 0.20, 17,592 ± 0.20, 18,861 ± 0.20 and 20,305 ± 0.20.